PYC Therapeutics Limited (PYC.AX)
Develops RNA drugs to treat genetic diseases like inherited blindness and brain disorders.
1.63+0.00%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+34.3%
The outlook
PYC trades near its 52-week highs with a strong-buy analyst consensus and an average price target implying substantial upside from current levels. The stock sits above both its 50- and 200-day moving averages, reflecting an upward price trajectory. Analyst coverage is modest at five firms.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 5 analysts
Price trendAbove its 50- & 200-day averages
52-week range86% of the way from its 52-week low to high
Price targetAvg target +131% vs current price
Analyst price target
~12-month · 5 analysts3.75average target+130.9% vs now
Now 1.63
Low 2.30High 5.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.60B
52-wk high
1.76
52-wk low
0.85
50-day avg
1.47
200-day avg
1.42
Trailing P/E
—